Sources close to the case confirmed to the Global Times newspaper that approval of the preparation is expected before July and that the municipality of Shanghai (east) will be the center of the whole process.
As detailed, that area equipped a factory with more than 100 refrigerators and tested the conveying system multiple times to ensure safe shipping of medicines.
Fosun Pharma, BioNTech’s Chinese partner, has provided the government with information about clinical trials and other required documents on the vaccine, made using mRNA (messenger RNA) technology and which will become the first of foreign origin to be applied in the Asian giant.
It was also learned that after approval, BioNTech could choose to send the fluid from Germany and China would pack it to go ahead with distribution and incorporate it into the massive vaccination campaign.
According to experts, this process responds to requests from some foreign residents here about the possibility of obtaining vaccines against Covid-19, obtained in different parts of the world.
They commented that this measure would benefit even the local reserves of immunization devices, global recognition, and the achievement of the Beijing 2022 Winter Olympics and the Paralympic Games.
But, in addition, it paves the way for research to determine whether using BioNTech-Pfizer in the first dose is more effective and then the second time to administer Chinese Sinovac, of the inactivated type.
China is betting on this idea in the midst of a debate about using substances created in various ways to boost immune protection against any of the SARS-CoV-2 mutations, which cause Covid-19.
It has 17 vaccines in various stages of testing, and since last July, it has been vaccinated with more than five vaccines, progressing to more than 205 million citizens and foreign citizens.
In addition, it has entered into agreements with several countries to supply them with medicines and has requested the WHO to incorporate medicines from Sinovac, Sinopharm and CanSinoBio into the Covax program.
The Asian giant made it clear this week that it still did not recognize injections created in other countries, in response to international reports that followed notification in the US regarding visa delivery to those who received visas from BioNTech-Pfizer, Moderna and Johnson & Johnson. Or another.
Room / year